Morgana Wingard/Global Fund Advocates NetworkA study from 11 low and middle-income countries has found that uptake of dolutegravir, a highly effective antiretroviral medication, is lowest for women of reproductive age with HIV. Although similar proportions of men and women were receiving dolutegravir before May 2018, profound disparities rapidly emerged after that date and persist despite the World Health Organization’s recommendation to expand its use to all adults and adolescents with HIV.
Led by Dr Matthew Romo of the City University of New York, researchers found that among patients starting treatment, only 20% of women aged 16-49 years were prescribed dolutegravir compared with 57% of men in the same age group. By the end of the follow-up (March 2020), dolutegravir uptake was 29% for women and 58% for men between 16 to 49 years. These findings are published in the January issue of Annals of Internal Medicine.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[Statement] MSF: Gilead stockholders: Demand Gilead sell HIV prevention drug to those who need it
-
Bhekisisa: In 2 years the Global Fund will cut South Africa’s grant by a quarter. In 8 years it will be gone
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.